AstraZeneca

British drugs group AstraZeneca and the University of Oxford said on Monday they will seek regulatory approval for their coronavirus vaccine after "effective" trials, in the latest potential boost to curbing the global outbreak.

The partners announced that while the vaccine showed an average 70-percent effectiveness, the level jumped to 90 percent depending on dosage. 

British drugs group AstraZeneca and the University of Oxford on Nov. 23 said their jointly-developed vaccine against COVID-19 has shown "an average efficacy of 70 percent" in trials.

AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, the latest drugmaker to unveil positive interim data in a scientific race to curb a global pandemic.

Doctor Valeriu Gheorghita, coordinator of the national COVID-19 vaccination campaign, said on Sunday evening that mobile vaccination centres will be set up to provide immunisation to people having difficulties moving and those with disabilities.

Today, the European Commission has reached a first agreement with the pharmaceutical company AstraZeneca to purchase a potential vaccine against COVID-19 as well as to donate to lower and middle income countries or re-direct to other European countries.

The goal is to ensure that they are fairly distributed around the world, the business daily "Handelsblatt" reported.

?he General Assembly of the Bulgarian Business Leaders Forum (BBLF) has elected four members of the Management Board at an annual meeting.

Petar Ivanov, Microsoft General Manager for Bulgaria and Macedonia, and Boryana Manolova, CEO of Siemens Bulgaria, are the new members of the BBLF Management Board.